Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

H3 Biomedicine to Present at the 36th Annual J.P. Morgan Healthcare Conference

H3 Biomedicine Inc.
Posted on: 02 Jan 18

H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of next generation cancer medicines using data science and precision chemistry product engine, today announced that Markus Warmuth, M.D., President and CEO of H3 Biomedicine, will present an overview of the company and its 2018 goals at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco.

During the presentation, Dr. Warmuth is expected to provide details about the company’s data science and precision chemistry product engine and its clinical pipeline of three differentiated, internally-generated cancer therapies, including:

  • H3B-8800, an oral, potent and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1) that is being developed by H3 Biomedicine as an anticancer therapeutic agent.
  • H3B-6527, a selective, orally bioavailable, and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4) that is being investigated for the treatment of advanced hepatocellular carcinoma (HCC).
  • H3B-6545, an orally bioavailable, potent and selective small molecule modulator of wild-type and mutant Estrogen Receptor (ERα).

For more information about H3 Biomedicine’s pipeline, please visit:
https://www.h3biomedicine.com/science/#pipeline

About H3 Biomedicine Inc.

H3 Biomedicine, a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, was established in 2011 as a subsidiary of Eisai's U.S. pharmaceutical operation, Eisai Inc. Leveraging this collaboration with Eisai Co., Ltd., who through this partnership provides essential research funding and access to the capabilities and resources of this global pharmaceutical company, H3 Biomedicine combines long-term vision with operational independence. Using modern synthetic chemistry, chemical biology, and human genetics, H3 Biomedicine seeks to bring the next generation of genomics-based cancer treatments to market with the goal of improving the lives of patients. For more information, please visit www.h3biomedicine.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180102005202/en/

Business Wire
www.businesswire.com

Last updated on: 02/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.